Carlsmed, a commercial-stage medical technology company, today announced the successful launch of its new digital production line. This technology will enable the company to deliver its Aprevo personalized spinal fusion implants to hospitals in fewer than 10 days.
“This advancement is more than just a technical achievement,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The reduced lead time makes aprevo available for surgeries with shorter scheduling windows, increasing addressable procedures and furthering our commitment to making personalized surgery accessible to every patient who needs it.”
Carlsmed’s current portfolio of patient-specific devices is indicated for use in lumbar spine fusion surgery. The company is developing patient-specific implants for cervical spine fusion surgery and received FDA Breakthrough Device designation for cervical fusions earlier this year. The launch of Aprevo for cervical fusions is expected by the end of 2025.
